2013 Annual Meeting Abstracts
Total Page:16
File Type:pdf, Size:1020Kb
Meeting Abstracts e1 ABSTRACTS 2013 Annual Meeting Abstracts This booklet contains the abstracts for the Scientific Session papers as submitted by the authors. Abstracts are in pre- sentation order by day and time. These abstracts are also available at www.ASSHAnnualMeeting.org. Financial Disclosure and FDA Status Symbol Key Society for Surgery of the Hand for educational purposes only. This material is not intended to represent the only, or — Something of Value The authors of those presentations necessarily the best methods or procedures appropriate for preceded by a have indicated that they have received the medical situation discussed, but rather is intended to something of value in the form of: research or institutional present an approach, view, statement, or opinion of the support, stock or stock options, equipment or services, paid authors or presenters, which may be helpful or of interest travel, royalties or as a consultant or employee of a com- to other practitioners. The attendees agree to participate in mercial company or institution related directly or indirectly this medical education program sponsored by ASSH with to the subject of the presentation. full knowledge and awareness that they waive any claim they may have against ASSH for reliance on any infor- © Nothing of Value — The authors of those presentations mation presented in this educational program. In addition, preceded by a © have indicated that they have not received the attendees also waive any claim they have against anything of value in the form of: research or institutional ASSH for any injury or other damage, which may result in support, stock or stock options, equipment or services, paid any way from their participation in the program. All of the travel, royalties or as a consultant or employee of a com- proceedings of this ASSH meeting, including the presen- mercial company or institution related directly or indirectly tation of scientific papers, are intended for limited publi- to the subject of the presentation. cation only, and all property rights in the material : Documentation of FDA Status — The authors of those presented, including common law copyright, are expressly presentations preceded by a : have indicated that the FDA reserved to the speaker and ASSH. No statement of pre- has not cleared the listed pharmaceuticals and/or medical sentation made is to be regarded as dedicated to the public devices for the use described in this presentation or that the domain. Any sound reproduction, transcript, or other use listed pharmaceuticals and/or medical devices are being of the material presented at this course without the discussed for an off-label use. permission of the speaker or ASSH is prohibited to the full extent of common law copyright in such material. The * AFSH Grant Research Acknowledgement — The authors approval of US Food and Drug Administration is required of those presentations preceded by a * have indicated that for procedures and drugs that are considered experimental. research related to their presentation was supported by an Instrumentation systems discussed and/or demonstrated in AFSH Research Grant. ASSH educational programs may not yet have received FDA approval. The ASSH does not view the existence of these interests or commitments as necessarily implying bias or decreasing the The ASSH assumes no responsibility or liability for the value of the presentations. use or misuse of any information, materials, or tech- Disclaimer niques described in the following abstracts and it makes no warranty, guarantee, or representation as to the ab- The material presented in this continuing medical educa- solute validity or sufficiency of any information tion program is being made available by the American provided. e2 ABSTRACTS PAPER 01 © Scott M. Tintle, MD L. Scott Levin, MD Best Papers Thursday, October 3, 2013 2:15e2:21 PM Hypothesis: We hypothesized that a rat model for composite tissue allo- Category: Evaluation/Diagnosis/Clinical Treatment transplantation (CTA) of the elbow joint could be developed. Keyword: Hand Methods: We developed an animal model for CTA of the elbow joint in rats. Microvascular elbow CTA was performed in 9 rats across a major histo- Comparison of Cortisone Injection and Percutaneous Trigger compatibility barrier. Three rats were treated with full-dose immunosu- Finger Release for Diabetic Trigger Fingers in 293 Patients pression consisting of cyclosporine until death. Three rats were provided Level 1 Evidence with 10 days of immunosuppression and then the cyslosporine was stopped. © Melissa Arief, MD Finally, 3 rats were used as a control and were given no immunosuppres- sion. Joint mobility and weight-bearing capability were assessed throughout © Mukund Patel, MD 90 days of life. Pedicle patency, bone blood flow, and histologic analysis Hypothesis: This study sought to compare the success rate of cortisone steroid were performed at the time of death. injection with that of percutaneous trigger finger release in diabetic patients. Results: In the cyclosporine group, forelimb activity was gradually recovered Methods: Data were collected over a 5-year period from 2008 to 2013. We over the postoperative 90 days. The operated extremity was used in daily studied 2 cohorts of patients with diabetes type 1 and 2 who were either activities such as ambulating and eating. There was little to no range of treated with local corticosteroid injection (N ¼ 191) or percutaneous trigger motion or use of the limb in the cyclosporine taper or the control groups. The release under local anesthesia in the office with a sterile 18-gauge needle vascular pedicles were patent at the time of death in the cyclosporine-treated (N ¼ 209). Patients were observed for at least 1 year. Patient demographics group, but not in the remaining groups. Micro-computed tomography scan included pain, trigger finger grade, and duration of symptoms. Patients were performed 3 months after the transplants revealed union at the bone junctions assessed at follow-up for pain, continued triggering, need for therapy after and the elbow joint appeared grossly normal upon death in the cyclosporine treatment, complications, and overall satisfaction. treatment group only. Incomplete healing was observed in the other 2 groups, Results: A total of 145 patients treated with corticosteroid injection were and the elbow joints were grossly destroyed. Histologic examination observed for 1 year and had an overall success rate based on patient revealed normal cartilage and bone cells in the cyclosporine-treated group, satisfaction of 75%. In this group, 4% required a second injection, 5% whereas the nontreated groups demonstrated lymphocytic infiltration and underwent a percutaneous trigger finger release, and 1 patient received an loss of normal histology. Flow cytometry of blood samples obtained on days open release. In the percutaneous release group, 147 patients were observed 14, 30, 60, and 90 showed no recipient cell chimerism in any of the groups. for 1 year. There was an overall success rate of 95%; 1 patient received a Summary: We have provided the first animal model for elbow CTA. In our corticosteroid injection. In both groups, there were no complications. cyclosporine-treated rats, animals regained near-normal function of fore- Summary: limbs after bone union and maintained grossly normal elbow cartilage. The results of this study demonstrate a greater rate of success of percu- Without cyslosporine treatment, the elbow transplants were rejected. taneous trigger finger release for diabetic trigger fingers compared with the standard corticosteroid injection. Royalties/Honoraria received from: Mavrek Medical This study demonstrated no complications for a large series of patients Receipt of Intellectual Property Rights/Patent Holder with: Sternal Talon demonstrating the safety of the percutaneous release in the office setting. REFERENCES PAPER 03 1. Pope DF, Wolfe SW. Safety and efficacy of percutaneous trigger finger release. J Hand Surg Am. 1995;20(2):280e283. Best Papers 2. Eastwood DM, Gupta KJ, Johnson DP. Percutaneous release of the trigger Thursday, October 3, 2013 2:35e2:41 PM finger: an office procedure. J Hand Surg Am. 1992;17(1):114e117. Category: Nerve/Neuromuscular 3. Bain GI, Wallwork NA. Percutaneous A1 pulley release: a clinical study. Hand Keyword: Forearm Surg. 1999;4(1):45e50. 4. Schramm JM, Nguyen M, Wongworawat MD. The safety of percutaneous A Collagen Conduit Versus Microsurgical Neurorrhaphy trigger finger release. Hand (N Y). 2008;3(1):44e46. 2-Year Follow-Up of a Prospective Blinded Clinical and 5. Calleja H, Tanchuling A, Alagar D, Tapia C, Macalalad A. Anatomic outcome of Electrophysiological Multicenter RCT percutaneous release among patients with trigger finger. J Hand Surg Am. Level 1 Evidence 2010;35(10):1671e1674. 6. Dahabra IA, Sawaqed IS. Percutaneous trigger finger release with 18-gauge Michel E. H. Boeckstyns, MD needle. Saudi Med J. 2007;28(7):1065e1067. © Christian Krarup, MD, FRCP fi 7. Stothard J, Kumar A. A safe percutaneous procedure for trigger nger release. J © Birgitta Rosen, OT, PhD R Coll Surg Edinb. 1994;39(2):116e117. © Joaquim Fores, MD 8. Patel MR, Moradia VJ. Percutaneous release of trigger digit with and without © cortisone injection. J Hand Surg Am. 1997;22(1):150e155. Allan Ibsen Sørensen, MD © Xavier Navarro, MD, PhD PAPER 02 Hypothesis: The hypothesis to be tested in our study was that use of the collagen nerve guide conduit for repair of traumatic short gap nerve lesions Best Papers in humans is associated